Absci (ABSI) Beta : N/A (As of May. 25, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Absci Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-25), Absci's Beta is Not available.

Absci Beta Historical Data

The historical data trend for Absci's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Absci Beta Chart

Absci Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Beta

Absci Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beta	Get a 7-Day Free Trial													-	-	-	-	-

Competitive Comparison of Absci's Beta

For the Biotechnology subindustry, Absci's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Absci's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Absci's Beta distribution charts can be found below:

* The bar in red indicates where Absci's Beta falls into.

Absci Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Absci (NAS:ABSI) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Absci Beta Related Terms

Thank you for viewing the detailed overview of Absci's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.

Absci (ABSI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Absci Corp (NAS:ABSI) » Definitions » Beta

Comparable Companies

Traded in Other Exchanges

N/A

Address

18105 SE Mill Plain Boulevard, Vancouver, WA, USA, 98683

Website

https://www.absci.com

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Executives

Frans Van Houten	director	18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Daniel A Rabinovitsj	director	400 W CESAR CHAVEZ, AUSTIN TX 78701
Andreas Busch	director	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Sarah Korman	officer: General Counsel	18105 SE MILL PLAIN BLVD, VANCOUVER WA 98660
Todd Bedrick	officer: VP, CCPAO	18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Joseph Sirosh	director	C/O COMPASS, INC., 155 AVENUE OF THE AMERICAS, SIXTH FLOOR, NEW YORK NY 10013
Sean Mcclain	director, 10 percent owner, officer: President and Chief Executive	18105 SE MILL PLAIN BLVD, SUITE 350, VANCOUVER WA 98683
Zachariah Jonasson	director	18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Eli Casdin	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Partners Master Fund, L.p.	director, 10 percent owner	WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Redmile Group, Llc	director, 10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Karen K Mcginnis	director	INSIGHT ENTERPRISES INC, 1305 WEST AUTO DRIVE, TEMPE AZ 85284
Redmile Biopharma Investments Ii, L.p.	director, 10 percent owner	LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129
Phoenix General Partner Ii Llc	10 percent owner	1700 S. EL CAMINO REAL, SUITE 335, SAN MATEO CA 94402
Nikhil Goel	officer: Chief Business Officer	101 E. 6TH STREET, SUITE 350, VANCOUVER WA 98660